FibroGen, Inc. (NASDAQ:FGEN) CEO Thane Wettig Buys 50,000 Shares

FibroGen, Inc. (NASDAQ:FGENGet Free Report) CEO Thane Wettig purchased 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The stock was bought at an average cost of $1.91 per share, for a total transaction of $95,500.00. Following the purchase, the chief executive officer now owns 470,178 shares in the company, valued at $898,039.98. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

FibroGen Stock Performance

FibroGen stock traded down $0.09 on Monday, reaching $1.71. The company’s stock had a trading volume of 488,949 shares, compared to its average volume of 2,864,676. The company has a market cap of $168.90 million, a price-to-earnings ratio of -0.62 and a beta of 0.66. The business’s fifty day moving average price is $1.54 and its 200 day moving average price is $1.01. FibroGen, Inc. has a twelve month low of $0.33 and a twelve month high of $20.90.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. StockNews.com assumed coverage on FibroGen in a research note on Friday, December 8th. They issued a “hold” rating on the stock. William Blair reaffirmed a “market perform” rating on shares of FibroGen in a research note on Tuesday, February 27th. One equities research analyst has rated the stock with a sell rating and four have given a hold rating to the company’s stock. According to MarketBeat.com, FibroGen presently has a consensus rating of “Hold” and an average target price of $17.00.

Check Out Our Latest Report on FibroGen

Hedge Funds Weigh In On FibroGen

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Assenagon Asset Management S.A. raised its position in shares of FibroGen by 49.7% during the third quarter. Assenagon Asset Management S.A. now owns 2,226,857 shares of the biopharmaceutical company’s stock worth $1,922,000 after acquiring an additional 739,166 shares during the last quarter. Primecap Management Co. CA raised its position in shares of FibroGen by 7.7% during the third quarter. Primecap Management Co. CA now owns 14,724,968 shares of the biopharmaceutical company’s stock worth $12,706,000 after acquiring an additional 1,047,380 shares during the last quarter. Armistice Capital LLC raised its position in shares of FibroGen by 81.2% during the third quarter. Armistice Capital LLC now owns 7,892,000 shares of the biopharmaceutical company’s stock worth $6,810,000 after acquiring an additional 3,536,000 shares during the last quarter. Acadian Asset Management LLC bought a new stake in shares of FibroGen during the third quarter worth $1,391,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of FibroGen during the third quarter worth $94,000. Institutional investors and hedge funds own 78.34% of the company’s stock.

FibroGen Company Profile

(Get Free Report)

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.

Read More

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.